ATGen Canada Inc. is a private immunodiagnostic company focused on the development of in vitro diagn
SANTA ANA, Calif., July 17, 2023 -- NKGen Biotech, Inc. (NKGen), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (NK) cell therapies, today announced the presentation of a poster with interim Phase...
Successful presentation today at the DDW2023 GI meeting of our poster “The Usefulness of a Natural Killer Cell Activity Blood Test in Prioritizing Colonoscopy Wait Times Amongst Covid-19-Induced Delays for Patients With a Positive F***l Immunochemical Test”
This is a clip from our first T**h Talk on colorectal cancer screening, hosted by Chana Cohen with guest speaker Dr. Marylise Boutros, colorectal surgeon and...
If you are attending SITC2022, come see our poster #1013. Using our biomarker test NK Vue, our collaborators have shown that NKA dynamics was an independent prognostic marker for OS in NSCLC patients receiving anti-PD-1/PD-L1 treatment. These findings highlight the value of testing for the ability of NK cells to carry out vital immune functions.
If you are attending SITC2022, come see our poster #1013. Using our biomarker test NK Vue, our collaborators have shown that NKA dynamics was an independent prognostic marker for OS in NSCLC patients receiving anti-PD-1/PD-L1 treatment. These findings highlight the value of testing for the ability of NK cells to carry out vital immune functions.
Background Even though immune checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients, their prognosis is still poor. Natural Killer (NK) cells are lymphocytes with distinct anti-cancer properties, and NK cell activity (NKA) may have a prognostic role. Similar...
SANTA ANA, Calif., October 17, 2022 — NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug...
In honor of , we would like to acknowledge patients affected by sarcoma, a rare cancer that accounts for only 1% of adult cancers. We are pursuing new treatment options for sarcoma patients through our SNK cell therapy clinical trials.
Background We aimed to evaluate the prognostic value of natural killer (NK) cell activity for patients with HER2 + advanced gastric cancer (AGC) treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab. Methods Forty-one patients with HER2 + AGC who received fluoropyrimid...
We are pleased to announce the latest study results for our NK Vue assay. The study entitled “The Potential Role of Peripheral Natural Killer Cells in Newly Diagnosed Inflammatory Bowel Disease or Colorectal Cancer”, was presented as a poster session at the Digestive Disease Week Conference (DDW2021). Seventy patients were enrolled in the study which consisted of patients with either colorectal cancer (CRC), Crohn’s disease (CD), or ulcerative colitis (UC). Each patient had their blood analyzed by the NK Vue assay to determine NK cell activity (NKA) levels. Compared to controls, NKA was found to be significantly reduced in CRC and in active CD patients, but not in active UC. The study demonstrates the use of NKA testing may help to assess the risk of CD or CRC prior to colonoscopy.
Link to the poster presentation below:
SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germany...
Please join this conversation!
March is Colorectal Cancer Awareness Month
/CNW/ - March is Colorectal Cancer Awareness Month, an important time to remember and support all those touched by colorectal cancer and a time to remind...
For our US followers
This will be very interesting!
Registration is open for next Wednesday's Summit4CI Speaker Series! Drs. Rebecca Auer of The Ottawa Hospital - L'Hôpital d'Ottawa & Chris O'Callaghan of Canadian Cancer Trials Group will discuss their COV-IMMUNO trial aiming to protect cancer patients against the effects of COVID19 - patient representative Judy Needham will provide a language summary as well. Details: https://bit.ly/34Pf3oH
Happy holidays - Joyeuses fêtes!
Proud to be part of this trial!
Today we're featuring an ongoing clinical trial focusing on protecting cancer patients from COVID-19 infection. It's led by Dr. Rebecca Auer of The Ottawa Hospital - L'Hôpital d'Ottawa and Dr. Chris O'Callaghan of Queen's University: https://bit.ly/3mBdqBt
Great news out of our US office!
We are excited to announce that NKMax America has entered into a clinical collaboration agreement with Affimed N.V. to investigate the combination of Affimed’s AFM24, a CD16A/EGFR targeted innate cell engager (ICE®), with NKMax America’s SNK01 autologous NK cell product. Pre-clinical data already shows substantive synergy between Affimed’s ICE® molecules and both NKMax America’s autologous and cryopreserved allogeneic NK cell therapy products. See press release at link below for more details on this collaboration.
https://www.globenewswire.com/news-release/2020/10/20/2110884/0/en/Affimed-and-NKMax-America-to-Study-the-Combination-of-AFM24-an-EGFR-Targeted-Innate-Cell-Engager-with-SNK01-Natural-Killer-Cell-Therapy.html
In pancreatic cancer patients, NK cell activity decreased as cancer progressed, and decreased NK cell activity was associated with poor clinical outcomes.
Poster presented today at ESMO using our NK Vue blood test: Study results show that high NK cell activity, as measured by NK Vue, after the first cycle of a PD-1/PD-L1 inhibitor is a favorable prognostic factor in patients with NSCLC.
Immunotherapy has improved survival for patients with incurable non-small cell lung cancer (NSCLC). The only validated biomarker is tumour PD-L1 expression. The aim of the present study was to evaluate NK cell activity as a prognostic biomarker in patients with NSCLC treated with PD-1/PD-L1 inhibito...
Proud to be part of this clinical trial where our NK Vue blood test is being used to measure immune response in these patients.
New on the HRI Portal: Protecting cancer patients from COVID-19: World-first clinical trial tests a novel immune-boosting strategy.
Read the media release here: https://hriportal.ca/protecting-cancer-patients-from-covid-19/
Exciting news from our US office!
SANTA ANA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the...
We are excited to announce that a translational research study will begin shortly, conducted by investigators at the Ottawa Hospital in Ottawa, Canada, to examine the activity of Natural Killer (NK) cells using our blood test NK Vue, in COVID-19 infected patients at high risk for serious complications. According to Dr. Rebecca Auer, one of the lead investigators, it seems highly likely that a robust innate immune response, in particular NK cell activity, predicts the ability to clear a COVID-19 infection, without prolonged hospitalization or ICU admission. COVID-19 positive patients will be followed by testing their NK cell activity throughout their hospitalization and recovery. “It is hoped that our test could later be used as a predictor of symptomatic infection and outcome in high risk patients” stated Katia Betito, Ph.D., President of ATGen Canada/NK Max Canada.
💙On Friday March 6th 2020, we are encouraging everyone to dress in blue to show support to those touched by colorectal cancer, while raising awareness about this preventable, treatable and beatable disease that is diagnosed in more than 28,300 Canadians each year. TOGETHER, WE CAN MAKE A DIFFERENCE! 💙
For more information about how to Go Blue: www.dressinblueday.ca
💙Le 6 mars 2020, nous encourageons tout le monde à s'habiller en bleu en guise de soutien aux personnes touchées par le cancer colorectal et pour sensibiliser les gens sur cette maladie évitable, traitable et guérissable diagnostiquée chez plus de 28 300 Canadiens chaque année.
ENSEMBLE, NOUS POUVONS CHANGER LES CHOSES!💙
Pour plus d'information sur la Journée tout en bleu : www.dressinblueday.ca
Happy holidays from ATGen Canada!
Joyeuses fêtes d'ATGen Canada!
Call for Volunteers: Colorectal Cancer Canada is looking for individuals who are passionate about the cause! A variety of volunteer opportunities are available for Bowl’n For My Colon. If interested, please contact Bunnie Schwartz at [email protected].
Appel aux bénévoles : Cancer colorectal Canada est à la recherche de personnes passionnées par la cause! De nombreux postes bénévoles sont offerts dans le cadre de l’événement Bowl’n For My Colon. Vous souhaitez nous donner un coup demain? Veuillez communiquer avec Bunnie Schwartz à l’adresse [email protected].
As of June 24, 2019, the f***l immunochemical test (FIT) is the recommended screening test in Ontario for people at average risk. ColonCancerCheck no longer recommends screening with the guaiac f***l occult blood (gFOBT).
Colorectal cancer (CRC), also known as bowel cancer, is Europe’s second biggest cancer killer. To mark European Colorectal Cancer Awareness Month 2019, Unite...
ATGen staff took a walk over to the CHUM to see Colorectal Cancer Canada's giant colon, helping to raise awareness for CRC!
Le personnel d'ATGen a fait un tour au CHUM pour voir le côlon géant de Cancer Colorectal Canada, pour aider à sensibiliser au CCR!
Our NK Vue stethoscope ID tags are in! DM us if you want one for your stethoscope. Thanks again InterConcept Inc.! Nos étiquettes ID pour stéthoscope sont rentrés! Envoyez-nous un message privé si vous en voulez une pour votre stéthoscope. Merci encore une fois, InterConcept Inc.!
Are you between 50 and 74 years of age and have a positive f***l test? Ask your doctor about NK Vue to test your immune system's natural killer cell activity. This information can predict if you are at higher risk for colorectal cancer.
Êtes-vous entre 50 et 74 ans et avez un test de selles positif? Demandez à votre médecin le test NK Vue, afin d'analyser l'activité des cellules tueuses naturelles de votre système immunitaire. Cette information peut prédire si vous présentez un risque plus élevé de cancer colorectal.
H4X1Z1
Be the first to know and let us send you an email when ATGen Canada/NKMax Canada posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to ATGen Canada/NKMax Canada:
#}